Covaxin phase 3 data shows 77.8% efficacy: Lancet

November 12, 2021 09:06

Hyderabad-based Bharat Biotech on Friday announced that the Lancet peer-review confirmed the efficacy analysis of Bharat Biotech's Covaxin.

As per phase-three clinical trials data, Covaxin demonstrates 77.8 per cent efficacy against symptomatic COVID-19.

'COVAXIN is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2 per cent,' the official statement issued by Bharat Biotech said citing the study by the Lancet.

'Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group,' said the company's statement.

Further, it said that Covaxin will be 93.4 per cent effective against severe symptomatic COVID-19.

'Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects experiencing serious adverse events,' it said.

'Efficacy data demonstrates 63.6 per cent protection against asymptomatic COVID-19, 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta and 70.8 per cent protection against all variants of SARS-CoV-2 virus,' Bharat Biotech added.

Dr Krishna Ella, Chairman and Managing Director (CMD) of Bharat Biotech said, 'The data from our product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin one of the most highly published COVID-19 vaccines in the world.'

"I am delighted to see that the phase III efficacy data has also been published in the Lancet. This itself speaks high about the strong position of Covaxin amongst other global front-runners COVID-19 vaccines," Dr Balram Bhargava, Director General, Indian Council of Medical Research (ICMR) said.

"The bench to bedside journey of Covaxin in less than 10 months showcases the immense strength of 'Atmanirbhar Bharat' along with the Indian academia and industry in fighting against the odds and carving a niche in the global community," Bhargava added.

Recently, the World Health Organisation granted emergency use listing to Covaxin enabling countries to expedite their regulatory approval to import and administer doses.

It has also received emergency use authorizations in several countries with applications in process in more than 50 countries worldwide, the statement added. -- ANI

« Back to LIVE

TOP STORIES

Former PM Dr Manmohan Singh passes away at 92

Former Indian Prime Minister Manmohan Singh passed away on Thursday night at the age of 92. He was brought to the emergency department of AIIMS Delhi in critical condition after "sudden loss of consciousness."

4th Test Updates: India eye early wickets on Day 2

Manmohan Singh dropped pre-medical course: Book

Former Indian Prime Minister Manmohan Singh, who died at the age of 92, dropped out of a pre-medical course after losing interest in the subject, according to a book by his daughter. Daman Singh's book "Strictly Personal: Manmohan and...

Steady progress in implementing LAC pact: China

He said that in recent times, based on the important consensus reached by the leaders of the two countries, China and India have maintained close communication on the border situation through diplomatic and military channels and achieved...

BJP got Rs 2,600cr donations in 2023-24, Cong Rs 281cr

During 2023-24, while the BJP received over Rs 723 crore worth of donations from Prudent Electoral Trust, it also got over Rs 127 crore from Triumph Electoral Trust and over Rs 17 lakh from Einzigartig Electoral Trust.